Loading clinical trials...
Loading clinical trials...
Alzheimer disease is hard, long and expensive to diagnose. In order to help the clinician, a new biomarker in Alzheimer disease seems to be very useful. The retina, as a window of the brain, could offer a new way to diagnose this common disease. Indeed, a retinal atrophy could especially appear in Alzheimer disease. Besides, many aspects about retinal alteration, visual function and their link with the disease deserve to be more explored. So as to fill these gaps, a new study about retinal specificity in Alzheimer disease appears to be relevant.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
Yes
CHU Amiens
Amiens, France
Start Date
January 13, 2021
Primary Completion Date
June 23, 2023
Completion Date
December 1, 2025
Last Updated
December 8, 2025
55
ACTUAL participants
Optical coherence tomography (OCT)
DIAGNOSTIC_TEST
Optical coherence tomograpohy angiography (OCTA)
DIAGNOSTIC_TEST
Lead Sponsor
Centre Hospitalier Universitaire, Amiens
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions